You have read all your free articles, to continue reading subscribe to read the rest of this content.
Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This marks the first regulatory approval for a type I interferon (type I IFN) receptor antagonist and the onlyAlready a subscriber Login You…
The European Commission has approved an update to the Victoza (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment. Victoza is the only GLP-1 that is proven to prevent CV events in peAlready a…
Ultomiris (ravulizumab) has been approved in the European Union for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH), an ultra-rare and severe blood disorder characterized by the destruction of red blood cells that can cause thrombosis (blood clots) anAlready a subscriber Login You have read all…
AstraZeneca and Merck & Co (MSD outside the US and Canada) have announced that the US Food and Drug Administration (FDA) has approved Lynparza for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced Already a subscriber Login You have read all…
